ANAB
ANAPTYSBIO, INC
Next earnings Aug 4, 2026 (after close) · consensus $-0.15 EPS, $31.4M rev
Last earnings -3.4% on 2026-05-12
$63.15
▲ +5.81%$63.15▲ +315.10%
over 1Y
L $12.93EODHDH $69.78
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.8%
1W+5.3%
1M+9.5%
3M+65.0%
YTD+110.7%
1Y+315.1%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 17 analysts
Buy
Revenue grew 157.0% YoY; but unprofitable (net margin -5.6%).
Revenue (FY2025) $235M · FY2025
ANAPTYSBIO, INC shows $235M in FY2025 revenue (+157.0% YoY), a -5.6% net margin, and -35.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $63.2M | $10.3M | $17.2M | $91.3M | $235M |
| Gross profit | — | — | — | — | — |
| Operating income | -$56.8M | -$115M | -$164M | -$115M | $47.9M |
| Net income | -$57.8M | -$129M | -$164M | -$145M | -$13.2M |
| Diluted EPS | -$2.11 | -$4.57 | -$6.08 | -$5.12 | -$0.46 |
| Net margin | -91.5% | -1251.3% | -953.7% | -159.1% | -5.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.58B
EV / EBITDA32.6
EV / Sales6.7
EV / FCF80.4
P / FCF92.6
PEG (trailing)—
Earnings yield-0.7%
FCF yield1.1%
Quality & risk
ROIC (est.)101.7%
Free cash flow$19.6M
Total debt—
Net cash$238M
Piotroski F-Score5/7
Capital returns
Buyback yield3.8%
Dividend yield (est.)—
Shareholder yield3.8%
Shares Δ YoY-6.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-04-28). Worth a closer look.
- 8-K Material agreement2026-06-22
- 8-K Reg FD disclosure2026-05-29
- 8-K Charter / bylaws change2026-05-21
- 8-K Earnings results2026-05-12
- 10-Q Quarterly report2026-05-12
- 8-K Officer / director change2026-05-11
- 10-K/A Restated periodic report2026-04-28
- 8-K/A Amended 8-K2026-04-24
- 8-K Officer / director change2026-04-20
Recent filings
all on EDGAR ↗144Filing2026-06-26open ↗8-KPeriod ending 2026-06-152026-06-22open ↗144Filing2026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗144Filing2026-06-16open ↗144Filing2026-06-15open ↗144Filing2026-06-12open ↗144Filing2026-06-11open ↗144Filing2026-06-10open ↗144Filing2026-06-09open ↗
Frequently asked
- Is ANAPTYSBIO, INC (ANAB) a buy?
- ANAB currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 157.0% YoY; but unprofitable (net margin -5.6%).
- What is ANAPTYSBIO, INC's quality score?
- ANAB scores 60.98039215686274/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001370053, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 7:03:52 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.